Clinical Trials
289 trialsRAINFOL-01
Genmab
EVEREST-2
A2 Biotherapeutics Inc.
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
National Institutes of Health Clinical Center (CC)
SELECTmeso
University of Southampton
DESCENT-1
A2 Biotherapeutics Inc.
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
National Institutes of Health Clinical Center (CC)
Rapid Autopsy and Procurement of Cancer Tissue
National Institutes of Health Clinical Center (CC)
iCaRe2
University of Nebraska
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Dana-Farber Cancer Institute
A Study of Sacituzumab Govitecan in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
TEADCO
Orion Corporation, Orion Pharma
BASECAMP-1
A2 Biotherapeutics Inc.
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
eVOLVE-Meso
AstraZeneca
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen Inc.
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
ANTARES
Instituto do Cancer do Estado de São Paulo
LuPARP
Vastra Gotaland Region
TraveraRTGx
Travera Inc
STEALTH-001
KaliVir Immunotherapeutics
Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma
Fudan University
DUAL-MESO-NK
Beijing Biotech
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics, Inc
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance
Massachusetts General Hospital
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ohio State University
SMARTER
University Health Network, Toronto
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
DuTOC
Dutch Society of Physicians for Pulmonology and Tuberculosis
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
Zhejiang University
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
University of Chicago
MesoPDT
University Hospital, Lille
MESO-PRIME
Royal Marsden NHS Foundation Trust
DREAM3R
PrECOG, LLC.
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Lumicell, Inc.
A Study of SGN-MesoC2 in Advanced Solid Tumors
Seagen Inc.
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute